Pinches Mark D, Betts Catherine J, Bickerton Susan J, Beattie Laura, Burdett Lisa D, Thomas Helen T, Derbyshire Nicola A, Moores Michele, Price Sally A
Safety Assessment, AstraZeneca, Alderley Park, Macclesfield, Cheshire, UK.
Toxicol Pathol. 2012 Apr;40(3):541-9. doi: 10.1177/0192623311432436. Epub 2012 Mar 6.
A number of novel urinary biomarkers have been identified and partially qualified for use as markers for renal injury in rats. We used two multiplex assays for these novel biomarkers to quantify biomarker concentration in serial urine collections from rats of both sexes administered varying concentrations of cisplatin. From these data, we calculate inter-individual variation and reference ranges from predose animals and intra-individual variation and reference change values from undosed control animals. The biomarkers evaluated are albumin, α glutathione s-transferase, glutathione S-transferase-yb1, lipocalin-2, kidney injury molecule-1, osteopontin, and renal papillary antigen 1. For any creatinine-corrected novel biomarkers, we found intra-individual variation to be no greater than 44% and inter-individual variation to be no greater than 46%. Reference change values for most corrected analytes (except osteopontin) were 50-100%, indicating that a >100% increase in analyte concentration between serial samples would be unlikely to be associated with inherent analytical or biological variation.
已经鉴定出多种新型尿液生物标志物,其中部分已具备用作大鼠肾损伤标志物的条件。我们使用两种多重检测方法对这些新型生物标志物进行检测,以量化来自接受不同浓度顺铂给药的雌雄大鼠的系列尿液样本中生物标志物的浓度。根据这些数据,我们计算了给药前动物的个体间变异和参考范围,以及未给药对照动物的个体内变异和参考变化值。所评估的生物标志物包括白蛋白、α谷胱甘肽S转移酶、谷胱甘肽S转移酶-yb1、lipocalin-2、肾损伤分子-1、骨桥蛋白和肾乳头抗原1。对于任何经肌酐校正的新型生物标志物,我们发现个体内变异不超过44%,个体间变异不超过46%。大多数校正分析物(骨桥蛋白除外)的参考变化值为50%-100%,这表明系列样本之间分析物浓度增加>100%不太可能与固有的分析或生物学变异相关。